محاسبات دزیمتری مولد درون تنی -Chitosan Ho166/Dy166 با استفاده از 4GEANT و MCNPX

سالک, نفیسه; وثوقی, سارا; بهرامی سامانی, علی

doi:10.24200/nst.2021.1295

نوع مقاله : مقاله پژوهشی

نویسندگان

¹ پژوهشکده چرخه سوخت هسته‌ای، پژوهشگاه علوم و فنون هسته‌ای، سازمان انرژی اتمی ایران، صندوق پستی: 8486-11365، تهران- ایران

² پژوهشکده‌ کاربرد پرتوها، پژوهشگاه علوم و فنون هسته‌ای، سازمان انرژی اتمی، صندوق پستی: 14155-1339، تهران- ایران

https://doi.org/10.24200/nst.2021.1295

چکیده

یکی از مهم‌ترین و مؤثرترین رادیونوکلیدهای به‌کار رفته در درمان تومورها، سرطان مغز استخوان و روماتوئید آرتریت، رادیونوکلید
هلمیوم-166 است. در بین رادیونوکلیدهای استفاده شده برای رادیوسینووکتومی، رادیونوکلید هلمیوم-166، به‌سبب ویژگی‌های مطلوب
همچون نیمه‌عمر کوتاه، گسیل ذرات بتا با انرژی مناسب، گسیل ذرات گاما با انرژی مناسب جهت تصویربرداری و امکان تولید بالا با استفاده از یک رآکتور با شار متوسط، مورد توجه قرار گرفته است. یک روش تحویل این رادیونوکلید به بافت هدف استفاده از مولد درون تنی دیسپرسیوم-166/ هلمیوم-166 کیتوزان است. تحویل رادیونوکلید هلمیوم-166 به بافت هدف از طریق این مولد درون تنی، باعث پرتوگیری حداقل بافت‌های غیر هدف و افزایش میزان در جذبی بافت هدف در مقایسه با رادیوداروهای مشابه دیگر می‌شود.در این مطالعه، دز جذبی رادیوکمپلکس -Chitosan Ho¹⁶⁶/Dy¹⁶⁶ در درمان رادیوسینووکتومی، با استفاده از 4GEANT و MCNPX محاسبه گردید و نتایج با یکدیگر مقایسه شده است. همچنین مقایسه نتایج دزیمتری رادیو کمپلکس مذکور با رادیوکمپلکسهای رایج مورد استفاده برای رادیوسینووکتومی، انجام شده است.

کلیدواژه‌ها

20.1001.1.17351871.1400.42.3.6.6

عنوان مقاله [English]

Dosimetry calculations of 166Dy/166Ho –Chitosan in vivo generator using GEANT4 and MCNPX

نویسندگان [English]

N. Salek ¹
S. Vosoughi ²
A. Bahrami Samani ¹

¹ Nuclear Fuel Cycle Research School, Nuclear Science and Technology Research Institute, AEOI, P.O.Box: 11365-8486, Tehran-Iran

² Radiation Application Research School, Nuclear Science and Technology Research Institute, AEOI, P.O.Box: 1339-14155, Tehran - Iran

چکیده [English]

The Holmium-166 radionuclide is one of the most effective radionuclides used to treat bone marrow cancer and rheumatoid arthritis. Among the recommended radionuclides used in radiation synovectomy, ¹⁶⁶Ho has got much attention due to suitable decay properties such as short half-life, its high beta energy, gamma-ray emission with suitable energy for nuclear imaging, and the possibility of large-scale production in medium flux reactor. One method to deliver ¹⁶⁶Ho to the target tissue is via the ¹⁶⁶Dy/¹⁶⁶Ho-Chitosan in vivo generator. Compared with other similar radiopharmaceuticals, using the in vivo generator to deliver ¹⁶⁶Ho, causes minimal non-target tissue exposure and increased absorbed dose in the target tissue. In this work, the absorbed dose of ¹⁶⁶Dy/¹⁶⁶Ho-Chitosan radio-complex for radio-synovectomy purposes was calculated by GEANT4 and MCNPX. The obtained results were compared with each other. In addition, the dosimetry results of the mentioned radio-complex have been compared with the common radio complexes used for radio-synovectomy.

کلیدواژه‌ها [English]

Radiosynovectomy
166Dy/166Ho
In vivo generator
Radio-complex
GEANT4
MCNPX

مراجع

1. E. Dadachova, et al., Separation of carrier-free¹⁶⁶Ho from Dy₂O₃ targets by partition chromatography and electrophoresis, J. Radioanal. Nucl. Ch. 199, 115 (1995).

2. R.J. Mumper, U.Y. Ryo, M. Jay, Neutron-Activated Holmium- 166-Poly (L-LacticAcid) Microspheres: A Potential Agent for the Internal Radiation Therapy of Hepatic Tumors, J. Nucl. Med. (1991).

3. Turner JH, et al., ¹⁶⁶Ho-microsphere liver radiotherapy: a preclinical SPECT dosimetry study in the pig, Nucl. Med. Commun. 15, 545 (1994).

4. M.R.A. Pillai, Metallic Radionuclides and Therapeutic Radiopharmaceuticals, (2010).

5. Susanta Lahiri, Kees J. Volkers, B. Wierczinski, Production of ¹⁶⁶Ho through ¹⁶⁴Dy(n,g) ¹⁶⁵Dy(n,g)¹⁶⁶Dy(b) ¹⁶⁶Ho and separation of ¹⁶⁶Ho, Appl. Radiat. Isot. 61, 1157 (2004).

6. L. F. Mausner, R. F. Straub, and S. C. Srivastava, The in vivo generator for radioimmunotherapy, J. Label Compd Radiopharm. 26, 498 (1989).

7. D. Ma, et al., Development of the Dy-166/Ho-166 in-vivo generator for radionuclide radiotherapy, 205th ACS national meeting, 26 (1993).

8. S. Mirzadeh, K. Kumar, O.A. Gansow, The Chemical Fate of ²¹²Bi-DOTA Formed by β-Decay of ²¹²Pb (DOTA), Radiochimca Acta. 60, 1 (1993).

9. Mirzadeh, ORNL Nuclear Medicine Program Progress Report, ORNL/TM-12159. 6 (1992).

10. Mirzadeh, ORNL Nuclear Medicine Program Progress Report, ORNL/TM-12485. 12 (1993b).

11. S.V. Smith, et al., [¹⁶⁶Dy] Dysprosium/[¹⁶⁶Ho] Holmium In Vivo Generator, APPI. Radiat. Hot. 46, 759 (1995).

12. J.R. Zeevaart, et al., Recoil and conversion electron implications to be taken into account in the design of therapeutic radiopharmaceuticals utilizing in vivo generators, J. Label Compd Radiopharm. 55, 115 (2012).

13. Evseev, Ivan G., et al., Comparison of SRIM, MCNPX and GEANT simulations with experimental data for thick Al absorbers, Appl. Radiat. Isot. 68, 948 (2010).

14. H. Safigholi, William Y. Song, Calculation of water equivalent ratios for various materials at proton energies ranging 10–500 MeV using MCNP, FLUKA, and GEANT4 Monte Carlo codes, Phys. Med. Biol. 63. 15 (2018).

15. Newhauser, Wayne D., et al., Benchmark measurements and simulations of dose perturbations due to metallic spheres in proton beams, Radiat. Meas. 58. 37 (2013).

16. S. Vosoughi, A.R. Jalilian, Simindokht Shirvani-Arani, et al. Preparation of ¹⁶⁶ Dy/¹⁶⁶ Ho-chitosan as an in vivo generator for radiosynovectomy. J. Radioanal. Nucl. Chem. 311. 3 (2017).

17. L. Johnson, et al., Beta-particle dosimetry in radiation synovectomy, Eur J Nucl Med Mol., 22, 977 (1995).

18. J. Villarreal-Barajas, G. Ferro-Flores, O. Hernandez-Oviedo, Experimental validation of Monte Carlo depth-dose calculations using radiochromic dye film dosimetry for a beta-gamma ¹⁵³Sm radionuclide applied to the treatment of rheumatoid arthritis, Radiat. Prot. Dosim. 101, 439 (2002).

19. T. André, et al., Comparison of Geant4-DNA simulation of S-values with other Monte Carlo codes, Nucl Instrum Meth B: Beam Interactions with Materials and Atoms. 319, 87 (2014).

20. M. Bardies, J.-F. Chatal, Absorbed doses for internal radiotherapy from 22 beta-emitting radionuclides: beta dosimetry of small spheres, Phys. Med. Biol. 39, 961 (1994).

21. M. Wu Junxiang, et al., Monte Carlo dosimetry of a new ⁹⁰Y brachytherapy source, J. Contemp Brachy-therapy. 7, 397 (2015).

22 T. Shi-Biao, et al., Geant4 used in medical physics and hadrontherapy technique, ‎Nucl. Sci. Tech. 17, 276 (2006).

23. Z. Rahman, et al., Absorbed dose estimations of ¹³¹I for critical organs using the GEANT4 Monte Carlo simulation code, Chin Phys C. 36, 1150 (2012).

24. L. Maigne, et al. Comparison of GATE/GEANT4 with EGSnrc and MCNP for electron dose calculations at energies between 15 keV and 20 MeV, Phys Med Biol. 56, 811(2011).

25. D. Sarrut, et al., A review of the use and potential of the GATE Monte Carlo simulation code for radiation therapy and dosimetry applications, J. Med. Phys. 41, 064301 (2014).

26. H. Uusijärvi, et al., Comparison of electron dose-point kernels in water generated by the Monte Carlo codes, PENELOPE, GEANT4, MCNPX, and ETRAN, Cancer Biother Radiopharm. 24, 461 (2009).

27. A.I. Kassis, S.J. Adelstein, Considerations in the selection of radionuclides for cancer therapy, Handbook of Radiopharmaceuticals: Radiochemistry and Applications, 767 (2003).

مجله علوم و فنون هسته ای

محاسبات دزیمتری مولد درون تنی -Chitosan Ho166/Dy166 با استفاده از 4GEANT و MCNPX

مراجع

مراجع

1. E. Dadachova, et al., Separation of carrier-free¹⁶⁶Ho from Dy₂O₃ targets by partition chromatography and electrophoresis, J. Radioanal. Nucl. Ch. 199, 115 (1995).

2. R.J. Mumper, U.Y. Ryo, M. Jay, Neutron-Activated Holmium- 166-Poly (L-LacticAcid) Microspheres: A Potential Agent for the Internal Radiation Therapy of Hepatic Tumors, J. Nucl. Med. (1991).

3. Turner JH, et al., ¹⁶⁶Ho-microsphere liver radiotherapy: a preclinical SPECT dosimetry study in the pig, Nucl. Med. Commun. 15, 545 (1994).

4. M.R.A. Pillai, Metallic Radionuclides and Therapeutic Radiopharmaceuticals, (2010).

5. Susanta Lahiri, Kees J. Volkers, B. Wierczinski, Production of ¹⁶⁶Ho through ¹⁶⁴Dy(n,g) ¹⁶⁵Dy(n,g)¹⁶⁶Dy(b) ¹⁶⁶Ho and separation of ¹⁶⁶Ho, Appl. Radiat. Isot. 61, 1157 (2004).

6. L. F. Mausner, R. F. Straub, and S. C. Srivastava, The in vivo generator for radioimmunotherapy, J. Label Compd Radiopharm. 26, 498 (1989).

7. D. Ma, et al., Development of the Dy-166/Ho-166 in-vivo generator for radionuclide radiotherapy, 205th ACS national meeting, 26 (1993).

8. S. Mirzadeh, K. Kumar, O.A. Gansow, The Chemical Fate of ²¹²Bi-DOTA Formed by β-Decay of ²¹²Pb (DOTA), Radiochimca Acta. 60, 1 (1993).

9. Mirzadeh, ORNL Nuclear Medicine Program Progress Report, ORNL/TM-12159. 6 (1992).

10. Mirzadeh, ORNL Nuclear Medicine Program Progress Report, ORNL/TM-12485. 12 (1993b).

11. S.V. Smith, et al., [¹⁶⁶Dy] Dysprosium/[¹⁶⁶Ho] Holmium In Vivo Generator, APPI. Radiat. Hot. 46, 759 (1995).

12. J.R. Zeevaart, et al., Recoil and conversion electron implications to be taken into account in the design of therapeutic radiopharmaceuticals utilizing in vivo generators, J. Label Compd Radiopharm. 55, 115 (2012).

13. Evseev, Ivan G., et al., Comparison of SRIM, MCNPX and GEANT simulations with experimental data for thick Al absorbers, Appl. Radiat. Isot. 68, 948 (2010).

14. H. Safigholi, William Y. Song, Calculation of water equivalent ratios for various materials at proton energies ranging 10–500 MeV using MCNP, FLUKA, and GEANT4 Monte Carlo codes, Phys. Med. Biol. 63. 15 (2018).

15. Newhauser, Wayne D., et al., Benchmark measurements and simulations of dose perturbations due to metallic spheres in proton beams, Radiat. Meas. 58. 37 (2013).

16. S. Vosoughi, A.R. Jalilian, Simindokht Shirvani-Arani, et al. Preparation of ¹⁶⁶ Dy/¹⁶⁶ Ho-chitosan as an in vivo generator for radiosynovectomy. J. Radioanal. Nucl. Chem. 311. 3 (2017).

17. L. Johnson, et al., Beta-particle dosimetry in radiation synovectomy, Eur J Nucl Med Mol., 22, 977 (1995).

18. J. Villarreal-Barajas, G. Ferro-Flores, O. Hernandez-Oviedo, Experimental validation of Monte Carlo depth-dose calculations using radiochromic dye film dosimetry for a beta-gamma ¹⁵³Sm radionuclide applied to the treatment of rheumatoid arthritis, Radiat. Prot. Dosim. 101, 439 (2002).

19. T. André, et al., Comparison of Geant4-DNA simulation of S-values with other Monte Carlo codes, Nucl Instrum Meth B: Beam Interactions with Materials and Atoms. 319, 87 (2014).

20. M. Bardies, J.-F. Chatal, Absorbed doses for internal radiotherapy from 22 beta-emitting radionuclides: beta dosimetry of small spheres, Phys. Med. Biol. 39, 961 (1994).

21. M. Wu Junxiang, et al., Monte Carlo dosimetry of a new ⁹⁰Y brachytherapy source, J. Contemp Brachy-therapy. 7, 397 (2015).

22 T. Shi-Biao, et al., Geant4 used in medical physics and hadrontherapy technique, ‎Nucl. Sci. Tech. 17, 276 (2006).

23. Z. Rahman, et al., Absorbed dose estimations of ¹³¹I for critical organs using the GEANT4 Monte Carlo simulation code, Chin Phys C. 36, 1150 (2012).

24. L. Maigne, et al. Comparison of GATE/GEANT4 with EGSnrc and MCNP for electron dose calculations at energies between 15 keV and 20 MeV, Phys Med Biol. 56, 811(2011).

25. D. Sarrut, et al., A review of the use and potential of the GATE Monte Carlo simulation code for radiation therapy and dosimetry applications, J. Med. Phys. 41, 064301 (2014).

26. H. Uusijärvi, et al., Comparison of electron dose-point kernels in water generated by the Monte Carlo codes, PENELOPE, GEANT4, MCNPX, and ETRAN, Cancer Biother Radiopharm. 24, 461 (2009).

27. A.I. Kassis, S.J. Adelstein, Considerations in the selection of radionuclides for cancer therapy, Handbook of Radiopharmaceuticals: Radiochemistry and Applications, 767 (2003).

دوره 42، شماره 3 - شماره پیاپی 97
مهر 1400
صفحه 44-51

محاسبات دزیمتری مولد درون تنی -Chitosan Ho166/Dy166 با استفاده از 4GEANT و MCNPX

مراجع

مراجع

1. E. Dadachova, et al., Separation of carrier-free166Ho from Dy2O3 targets by partition chromatography and electrophoresis, J. Radioanal. Nucl. Ch. 199, 115 (1995).

2. R.J. Mumper, U.Y. Ryo, M. Jay, Neutron-Activated Holmium- 166-Poly (L-LacticAcid) Microspheres: A Potential Agent for the Internal Radiation Therapy of Hepatic Tumors, J. Nucl. Med. (1991).

3. Turner JH, et al., 166Ho-microsphere liver radiotherapy: a preclinical SPECT dosimetry study in the pig, Nucl. Med. Commun. 15, 545 (1994).

4. M.R.A. Pillai, Metallic Radionuclides and Therapeutic Radiopharmaceuticals, (2010).

5. Susanta Lahiri, Kees J. Volkers, B. Wierczinski, Production of 166Ho through 164Dy(n,g) 165Dy(n,g) 166Dy(b) 166Ho and separation of 166Ho, Appl. Radiat. Isot. 61, 1157 (2004).

6. L. F. Mausner, R. F. Straub, and S. C. Srivastava, The in vivo generator for radioimmunotherapy, J. Label Compd Radiopharm. 26, 498 (1989).

7. D. Ma, et al., Development of the Dy-166/Ho-166 in-vivo generator for radionuclide radiotherapy, 205th ACS national meeting, 26 (1993).

8. S. Mirzadeh, K. Kumar, O.A. Gansow, The Chemical Fate of 212Bi-DOTA Formed by β-Decay of 212Pb (DOTA), Radiochimca Acta. 60, 1 (1993).

9. Mirzadeh, ORNL Nuclear Medicine Program Progress Report, ORNL/TM-12159. 6 (1992).

10. Mirzadeh, ORNL Nuclear Medicine Program Progress Report, ORNL/TM-12485. 12 (1993b).

11. S.V. Smith, et al., [166Dy] Dysprosium/[166Ho] Holmium In Vivo Generator, APPI. Radiat. Hot. 46, 759 (1995).

12. J.R. Zeevaart, et al., Recoil and conversion electron implications to be taken into account in the design of therapeutic radiopharmaceuticals utilizing in vivo generators, J. Label Compd Radiopharm. 55, 115 (2012).

13. Evseev, Ivan G., et al., Comparison of SRIM, MCNPX and GEANT simulations with experimental data for thick Al absorbers, Appl. Radiat. Isot. 68, 948 (2010).

14. H. Safigholi, William Y. Song, Calculation of water equivalent ratios for various materials at proton energies ranging 10–500 MeV using MCNP, FLUKA, and GEANT4 Monte Carlo codes, Phys. Med. Biol. 63. 15 (2018).

15. Newhauser, Wayne D., et al., Benchmark measurements and simulations of dose perturbations due to metallic spheres in proton beams, Radiat. Meas. 58. 37 (2013).

16. S. Vosoughi, A.R. Jalilian, Simindokht Shirvani-Arani, et al. Preparation of 166 Dy/166 Ho-chitosan as an in vivo generator for radiosynovectomy. J. Radioanal. Nucl. Chem. 311. 3 (2017).

17. L. Johnson, et al., Beta-particle dosimetry in radiation synovectomy, Eur J Nucl Med Mol., 22, 977 (1995).

18. J. Villarreal-Barajas, G. Ferro-Flores, O. Hernandez-Oviedo, Experimental validation of Monte Carlo depth-dose calculations using radiochromic dye film dosimetry for a beta-gamma 153Sm radionuclide applied to the treatment of rheumatoid arthritis, Radiat. Prot. Dosim. 101, 439 (2002).

19. T. André, et al., Comparison of Geant4-DNA simulation of S-values with other Monte Carlo codes, Nucl Instrum Meth B: Beam Interactions with Materials and Atoms. 319, 87 (2014).

20. M. Bardies, J.-F. Chatal, Absorbed doses for internal radiotherapy from 22 beta-emitting radionuclides: beta dosimetry of small spheres, Phys. Med. Biol. 39, 961 (1994).

21. M. Wu Junxiang, et al., Monte Carlo dosimetry of a new 90Y brachytherapy source, J. Contemp Brachy-therapy. 7, 397 (2015).

22 T. Shi-Biao, et al., Geant4 used in medical physics and hadrontherapy technique, ‎Nucl. Sci. Tech. 17, 276 (2006).

23. Z. Rahman, et al., Absorbed dose estimations of 131I for critical organs using the GEANT4 Monte Carlo simulation code, Chin Phys C. 36, 1150 (2012).

24. L. Maigne, et al. Comparison of GATE/GEANT4 with EGSnrc and MCNP for electron dose calculations at energies between 15 keV and 20 MeV, Phys Med Biol. 56, 811(2011).

25. D. Sarrut, et al., A review of the use and potential of the GATE Monte Carlo simulation code for radiation therapy and dosimetry applications, J. Med. Phys. 41, 064301 (2014).

26. H. Uusijärvi, et al., Comparison of electron dose-point kernels in water generated by the Monte Carlo codes, PENELOPE, GEANT4, MCNPX, and ETRAN, Cancer Biother Radiopharm. 24, 461 (2009).

27. A.I. Kassis, S.J. Adelstein, Considerations in the selection of radionuclides for cancer therapy, Handbook of Radiopharmaceuticals: Radiochemistry and Applications, 767 (2003).

دوره 42، شماره 3 - شماره پیاپی 97مهر 1400صفحه 44-51

1. E. Dadachova, et al., Separation of carrier-free¹⁶⁶Ho from Dy₂O₃ targets by partition chromatography and electrophoresis, J. Radioanal. Nucl. Ch. 199, 115 (1995).

3. Turner JH, et al., ¹⁶⁶Ho-microsphere liver radiotherapy: a preclinical SPECT dosimetry study in the pig, Nucl. Med. Commun. 15, 545 (1994).

5. Susanta Lahiri, Kees J. Volkers, B. Wierczinski, Production of ¹⁶⁶Ho through ¹⁶⁴Dy(n,g) ¹⁶⁵Dy(n,g)¹⁶⁶Dy(b) ¹⁶⁶Ho and separation of ¹⁶⁶Ho, Appl. Radiat. Isot. 61, 1157 (2004).

8. S. Mirzadeh, K. Kumar, O.A. Gansow, The Chemical Fate of ²¹²Bi-DOTA Formed by β-Decay of ²¹²Pb (DOTA), Radiochimca Acta. 60, 1 (1993).

11. S.V. Smith, et al., [¹⁶⁶Dy] Dysprosium/[¹⁶⁶Ho] Holmium In Vivo Generator, APPI. Radiat. Hot. 46, 759 (1995).

16. S. Vosoughi, A.R. Jalilian, Simindokht Shirvani-Arani, et al. Preparation of ¹⁶⁶ Dy/¹⁶⁶ Ho-chitosan as an in vivo generator for radiosynovectomy. J. Radioanal. Nucl. Chem. 311. 3 (2017).

18. J. Villarreal-Barajas, G. Ferro-Flores, O. Hernandez-Oviedo, Experimental validation of Monte Carlo depth-dose calculations using radiochromic dye film dosimetry for a beta-gamma ¹⁵³Sm radionuclide applied to the treatment of rheumatoid arthritis, Radiat. Prot. Dosim. 101, 439 (2002).

21. M. Wu Junxiang, et al., Monte Carlo dosimetry of a new ⁹⁰Y brachytherapy source, J. Contemp Brachy-therapy. 7, 397 (2015).

23. Z. Rahman, et al., Absorbed dose estimations of ¹³¹I for critical organs using the GEANT4 Monte Carlo simulation code, Chin Phys C. 36, 1150 (2012).

دوره 42، شماره 3 - شماره پیاپی 97
مهر 1400
صفحه 44-51